Crucell Appoints Executive Director Of Business Development for Its Antibody Business

Apr 10, 2001, 01:00 ET from Crucell N.V.

    LEIDEN, Netherlands, April 10 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL)
 (EAX Amsterdam: CRXL), a leading biotechnology company focused on the
 discovery of unique drug targets on disease associated cells and on the
 development of huMADE(TM) biopharmaceuticals, today announced that it has
 appointed Arthur Lahr as Executive Director of Business Development for its
 antibody business.
     Mr. Lahr will be responsible for the commercialisation of Crucell's
 antibody products that are derived from its MAbstract(TM) target discovery and
 antibody phage display technology.  Mr. Lahr joins Crucell after having worked
 for more than six years at McKinsey & Company in both Amsterdam and New York,
 where among other things, he set up and supported business development for
 start up companies.  Through his work at McKinsey, he has gained extensive
 experience in the healthcare, technology and banking industries.  Prior to
 working at McKinsey, Mr. Lahr worked as an engineer at Unilever.  He has a
 background in Applied Physics through his degree at Delft University of
 Technology, and holds an MBA from INSEAD at Fontainebleau.
     Dinko Valerio, President and Chief Executive Officer for Crucell
 commented: "We are pleased to welcome Arthur to Crucell.  His experience and
 skills will give a boost to our commercial antibody related activities, which
 were only started last summer.  This area of research is very important to us,
 as it offers tremendous opportunities for the discovery of new drug targets
 and antibody based products that we can commercialise."
 
     About Crucell
     Crucell is a leading biotechnology company focused on the discovery of
 unique drug targets on diseased cells and on the development of huMADE(TM)
 biopharmaceuticals.  Crucell's two broadly applicable human technology
 platforms form the basis for this.  The first is a human cell line expression
 platform, PER.C6(TM), on which a wide range of biopharmaceuticals can be
 developed and manufactured, such as vaccines, antibodies, therapeutic proteins
 and gene therapy products.  The second technology is called MAbstract(TM), a
 set of tools based on phage antibody-display libraries and proprietary
 subtraction and selection technology, to discover novel drug targets and
 develop human monoclonal antibodies as therapeutics for a variety of diseases.
     Crucell makes its technologies available under exclusive or non-exclusive
 license agreements, and has currently signed 16 agreements with major
 pharmaceutical and biotechnology companies for its PER.C6(TM) technology.
 Crucell focuses on the development of therapeutics for treatment of cancer,
 inflammatory diseases and for the prevention and treatment of influenza and
 other infectious diseases.
     Crucell currently employs approximately 130 people in its facilities in
 Leiden, Utrecht and Leuven (Belgium).
 
     This press release contains forward-looking statements that involve
 inherent risks and uncertainties.  We have identified certain important
 factors that may cause actual results to differ materially from those
 contained in such forward-looking statements.  See our Registration Statement,
 as filed on Form F-1 with the U.S. Securities and Exchange Commission on
 October 26, 2000 (the "Registration Statement") and the section of the
 Registration Statement entitled "Risk Factors."
 
     For further information please contact:
 
     Crucell N.V.
     Annemarie Haverhals
     Vice President, Corporate Affairs
     Tel. +31-71-524-8722
     Fax. +31-71-524-8702
     a.haverhals@crucell.com
     www.crucell.com
 
     Noonan Russo U.S.
     Lisa Baumgartner
     Tel. +1-212-696-4455 ext. 245
     Fax. +1-212-696-9180
     l.baumgartner@noonanrusso.com
 
     Noonan Russo Ltd
     Veronica Sellar
     Tel. +44-20-7726-4452
     Fax. +44-20-7726-4453
     v.sellar@noonanrusso.co.uk
 
     Hill & Knowlton Nederland B.V.
     Jeroen van Seeters
     Tel. +31-20-404-4707
     Fax. +31-20-644-9736
     Jvseeters@hillandknowlton.com
 
 

SOURCE Crucell N.V.
    LEIDEN, Netherlands, April 10 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL)
 (EAX Amsterdam: CRXL), a leading biotechnology company focused on the
 discovery of unique drug targets on disease associated cells and on the
 development of huMADE(TM) biopharmaceuticals, today announced that it has
 appointed Arthur Lahr as Executive Director of Business Development for its
 antibody business.
     Mr. Lahr will be responsible for the commercialisation of Crucell's
 antibody products that are derived from its MAbstract(TM) target discovery and
 antibody phage display technology.  Mr. Lahr joins Crucell after having worked
 for more than six years at McKinsey & Company in both Amsterdam and New York,
 where among other things, he set up and supported business development for
 start up companies.  Through his work at McKinsey, he has gained extensive
 experience in the healthcare, technology and banking industries.  Prior to
 working at McKinsey, Mr. Lahr worked as an engineer at Unilever.  He has a
 background in Applied Physics through his degree at Delft University of
 Technology, and holds an MBA from INSEAD at Fontainebleau.
     Dinko Valerio, President and Chief Executive Officer for Crucell
 commented: "We are pleased to welcome Arthur to Crucell.  His experience and
 skills will give a boost to our commercial antibody related activities, which
 were only started last summer.  This area of research is very important to us,
 as it offers tremendous opportunities for the discovery of new drug targets
 and antibody based products that we can commercialise."
 
     About Crucell
     Crucell is a leading biotechnology company focused on the discovery of
 unique drug targets on diseased cells and on the development of huMADE(TM)
 biopharmaceuticals.  Crucell's two broadly applicable human technology
 platforms form the basis for this.  The first is a human cell line expression
 platform, PER.C6(TM), on which a wide range of biopharmaceuticals can be
 developed and manufactured, such as vaccines, antibodies, therapeutic proteins
 and gene therapy products.  The second technology is called MAbstract(TM), a
 set of tools based on phage antibody-display libraries and proprietary
 subtraction and selection technology, to discover novel drug targets and
 develop human monoclonal antibodies as therapeutics for a variety of diseases.
     Crucell makes its technologies available under exclusive or non-exclusive
 license agreements, and has currently signed 16 agreements with major
 pharmaceutical and biotechnology companies for its PER.C6(TM) technology.
 Crucell focuses on the development of therapeutics for treatment of cancer,
 inflammatory diseases and for the prevention and treatment of influenza and
 other infectious diseases.
     Crucell currently employs approximately 130 people in its facilities in
 Leiden, Utrecht and Leuven (Belgium).
 
     This press release contains forward-looking statements that involve
 inherent risks and uncertainties.  We have identified certain important
 factors that may cause actual results to differ materially from those
 contained in such forward-looking statements.  See our Registration Statement,
 as filed on Form F-1 with the U.S. Securities and Exchange Commission on
 October 26, 2000 (the "Registration Statement") and the section of the
 Registration Statement entitled "Risk Factors."
 
     For further information please contact:
 
     Crucell N.V.
     Annemarie Haverhals
     Vice President, Corporate Affairs
     Tel. +31-71-524-8722
     Fax. +31-71-524-8702
     a.haverhals@crucell.com
     www.crucell.com
 
     Noonan Russo U.S.
     Lisa Baumgartner
     Tel. +1-212-696-4455 ext. 245
     Fax. +1-212-696-9180
     l.baumgartner@noonanrusso.com
 
     Noonan Russo Ltd
     Veronica Sellar
     Tel. +44-20-7726-4452
     Fax. +44-20-7726-4453
     v.sellar@noonanrusso.co.uk
 
     Hill & Knowlton Nederland B.V.
     Jeroen van Seeters
     Tel. +31-20-404-4707
     Fax. +31-20-644-9736
     Jvseeters@hillandknowlton.com
 
 SOURCE  Crucell N.V.